PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (...
May 08 2018 - 12:00AM
REGULATED INFORMATION
GHENT, Belgium, 8
May 2018 - Ablynx [Euronext Brussels and
Nasdaq: ABLX] today announced, in accordance with Article 14 of
the Belgian Law of 2 May 2007 regarding the publication of major
shareholdings in issuers whose securities are admitted to trading
on a regulated market (the "Transparency Law"), that it received
two notification of shareholdings from BlackRock, Inc. on 3 and 7
May 2018.
In a first notification,
BlackRock, Inc. (taking into account the holdings of its subsidiary
undertakings) notified Ablynx that on 2 May 2018 it has downward
crossed the 3% threshold of voting rights attached to shares for
BlackRock, Inc. and downward crossed the 5% threshold of the total
holding in voting rights for BlackRock, Inc.
In a second notification,
BlackRock, Inc. notified Ablynx that on 3 May 2018 it has upward
crossed the 3% threshold of voting rights attached to shares for
BlackRock, Inc. and upward crossed the 5% threshold of the total
holding in voting rights for BlackRock, Inc.
BlackRock, Inc. now holds a total
of 3,861,453 voting securities of Ablynx, representing 5.12% of the
current 75,406,551 outstanding voting rights of Ablynx (versus
5.55% notified previously on 16 April 2018).
The most recent notification
contains the following information:
-
Reason for the
notification: acquisition or disposal of voting securities or
voting rights
-
Notification by: a parent
undertaking or a controlling person
-
Persons subject to the
notification requirement:
Name |
Address (for legal entities) |
BlackRock, Inc. |
55
East 52nd Street, New York, NY, 10055, U.S.A. |
BlackRock
(Netherlands) B.V. |
Rembrandt
Tower, 17th floor, Amstelplein, Amsterdam, Netherlands |
BlackRock
Advisors (UK) Limited |
12
Throgmorton Avenue, London, EC2N 2DL, U.K. |
BlackRock
Advisors, LLC |
100
Bellevue Parkway, Wilmington, DE, 19809, U.S.A. |
BlackRock
Asset Management Canada Limited |
161 Bay
Street, Suite 2500, Toronto, Ontario, M5J 2S1, Canada |
BlackRock
Asset Management Deutschland AG |
Max-Joseph-Straße 6, Munich, 80333, Germany |
BlackRock
Asset Management North Asia Limited |
15/F,
16/F, 17/F Citibank Tower & 17/F ICBC Tower, 3 Garden Road,
Central, Hong Kong |
BlackRock
Financial Management, Inc. |
55 East
52nd Street, New York, NY, 10055, U.S.A. |
BlackRock
Fund Advisors |
400 Howard
Street, San Francisco, CA, 94105, U.S.A. |
BlackRock
Institutional Trust Company, National Association |
400 Howard
Street, San Francisco, CA, 94105, U.S.A. |
BlackRock
Investment Management (Australia) Limited |
Level 37,
Chifley Tower, 2 Chifley Square, Sydney NSW 2000 Australia |
BlackRock
Investment Management (UK) Limited |
12
Throgmorton Avenue, London, EC2N 2DL, U.K. |
BlackRock
Investment Management, LLC |
1
University Square Drive, Princeton, NJ, 8540, U.S.A. |
BlackRock
Japan Co., Ltd. |
1-8-3
Marunouchi Chiyoda-ku, Trust Tower Main, Tokyo, 100-8217,
Japan |
-
Transaction date: 3 May
2018
-
Threshold that is crossed:
5% (of the total holding)
-
Denominator:
75,406,551
-
Details of the
notification:
Name of select subsidiaries of BlackRock |
% of voting rights |
% of voting rights held through financial
instruments* |
Total of both |
BlackRock
(Netherlands) B.V. |
0.01% |
|
0.01% |
BlackRock
Advisors (UK) Limited |
1.08% |
0.04%
1 |
1.12% |
BlackRock
Asset Management Canada Limited |
0.01% |
|
0.01% |
BlackRock
Asset Management Deutschland AG |
0.25% |
|
0.25% |
BlackRock
Asset Management North Asia Limited |
0.00% |
|
|
BlackRock
Fund Advisors |
0.85% |
|
0.85% |
BlackRock
Institutional Trust Company, National Association |
0.52% |
0.11%
2 |
0.63% |
BlackRock
Investment Management (Australia) Limited |
0.00% |
|
0.00% |
BlackRock
Investment Management (UK) Limited |
0.13% |
|
0.13% |
BlackRock
Investment Management, LLC |
0.01% |
0.80%
2 |
0.81% |
BlackRock
Japan Co., Ltd |
0.32% |
|
0.32% |
BlackRock
Advisors, LLC |
|
0.33%2 |
0.33% |
BlackRock
Financial Management, Inc. |
|
0.67%
2 |
0.67% |
TOTAL |
3.18% |
1.94% |
5.12% |
* Type of
financial instrument: 1'Securities
lent' and 2'Contract for
Difference'
-
Chain of controlled
undertakings through which the holding is effectively being
held: Please see the full chain of control in the Transparency
Notification.
-
Additional information: The
disclosure obligations arose due to voting rights attached to
shares going below and above 3% and the total holding in voting
rights going below and above 5%.
A full version of the transparency
notification is available on Ablynx website, under the section
Investors.
The Articles of the Association of
Ablynx NV provide for shareholders notification threshold of 3%, 5%
or a multiple of 5% of the total number of existing voting
rights.
About
Ablynx
Ablynx is a biopharmaceutical
company engaged in the development of Nanobodies, proprietary
therapeutic proteins based on single-domain antibody fragments,
which combine the advantages of conventional antibody drugs with
some of the features of small-molecule drugs. Ablynx is dedicated
to creating new medicines which will make a real difference to
society. Today, the Company has more than 45 proprietary and
partnered programmes in development in various therapeutic areas
including inflammation, haematology, immuno-oncology, oncology and
respiratory disease. The Company has collaborations with multiple
pharmaceutical companies including AbbVie; Boehringer Ingelheim;
Eddingpharm; Merck & Co., Inc., Kenilworth, New Jersey, USA;
Merck KGaA; Novo Nordisk; Sanofi and Taisho Pharmaceuticals. The
Company is headquartered in Ghent, Belgium. More information can be
found on www.ablynx.com.
On 29 January 2018, Sanofi made an
offer to acquire all of Ablynx's outstanding ordinary shares
(including shares represented by American Depository Shares (ADSs),
warrants and convertible bonds) at a price of €45 per share, which
represents an aggregate equity value of approximately €3.9 billion.
The proposed transaction was unanimously approved by both the
Sanofi and Ablynx Board of Directors. The initial tender offer
commenced on 4 April 2018 and expired on 4 May 2018, subject to
extension. Sanofi has published an offer document in which it set
out the full details of its tender offer, and the Board of
Directors of Ablynx published a response memorandum ('memorie van
antwoord'), in which it set out its position on the tender
offer.
For more
information, please contact
Ablynx:
Dr Edwin Moses
CEO
t: +32 (0)9 262 00 07
m: +32 (0)473 39 50 68
e: edwin.moses@ablynx.com
Lies Vanneste
Director Investor Relations
t: +32 (0)9 262 01 37
m: +32 (0)498 05 35 79
e: lies.vanneste@ablynx.com
Follow us on Twitter @AblynxABLX
Ablynx media
relations:
Consilium Strategic Communications
Mary-Jane Elliott, Philippa Gardner, Sukaina Virji
t: +44 (0)20 3709 5700
e: ablynx@consilium-comms.com
Joele Frank,
Wilkinson Brimmer Katcher
Dan Katcher or Joseph Sala
t: +1 212-355-4449
pdf version of the press
release
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Ablynx via Globenewswire
Ablynx NV (NASDAQ:ABLX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Ablynx NV (NASDAQ:ABLX)
Historical Stock Chart
From Sep 2023 to Sep 2024